Therefore, understanding the molecular mechanisms underlying intrinsic resistance and early refractoriness to lorlatinib is critical for establishing novel therapeutic strategies in patients with ALK-rearranged NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.